Roche Holding Ltd
RO
ISIN CH0012032113 / Valor 1203211
Roche Holding Ltd
UMushroom community rating:
About company
Roche Holding Ltd is a global healthcare company headquartered in Basel, Switzerland, renowned for its contributions to pharmaceuticals and diagnostics. The company is dedicated to developing innovative treatments across major disease areas, with a strong emphasis on translating scientific excellence into effective medicines. Roche's pharmaceutical division is particularly focused on oncology, immunology, infectious diseases, ophthalmology, and neuroscience, aiming to address unmet medical needs and improve patient outcomes. In addition to its pharmaceutical endeavors, Roche is a leader in in-vitro diagnostics and tissue-based cancer diagnostics, providing comprehensive solutions that enhance disease detection and management. Through its commitment to research and development, Roche continues to play a pivotal role in advancing healthcare and delivering transformative therapies worldwide.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (14.03.2026):
Roche Holding Ltd — Q4/Full‑year 2024 (results for year ended 31 December 2024): Group sales were CHF 60.5 billion (+7% at constant exchange rates, CER), core operating profit rose to CHF 20.8 billion (+14% CER) and core EPS increased to CHF 18.80 (+7% CER). On an IFRS basis net income fell to CHF 9.2 billion (−19% CER) mainly due to goodwill and intangible impairments; free cash flow strengthened to CHF 15.3 billion (+43% CER). The Swiss franc appreciation weighed on reported CHF figures.
Headline results
Sales CHF 60.5bn (+7% CER), IFRS operating profit CHF 13.4bn (−6% CER), core operating profit CHF 20.8bn (+14% CER). IFRS net income CHF 9.2bn (−19% CER); core net income CHF 16.0bn (+7% CER). Core EPS CHF 18.80 (+7% CER); diluted IFRS EPS CHF 10.31 (−28% in CHF).
Impairments and non‑core items
IFRS results include major non‑core charges: CHF 3.2bn goodwill impairment (Flatiron Health and Spark Therapeutics), CHF 1.4bn intangible asset impairments and CHF 1.9bn restructuring charges, which materially reduced IFRS net income versus the core measures.
Division performance
Pharmaceuticals: sales CHF 46.2bn (+8% CER) driven by Vabysmo, Phesgo, Ocrevus and Hemlibra. Diagnostics: sales CHF 14.3bn (+4% CER); excluding COVID products Diagnostics sales grew ~8% CER (immunodiagnostics strength).
Cash flow and balance sheet
Operating free cash flow CHF 20.1bn (+34% CER); free cash flow CHF 15.3bn (+43% CER). Net debt reduced to CHF 17.3bn (from CHF 18.7bn). Board proposes a CHF 9.70 dividend per share (+1%).
R&D, costs and taxes
Core R&D spend ~CHF 13.0bn (flat on CER); selling, general & admin and cost controls supported core margin expansion. Core financing costs rose (issuance of new debt) and the effective core tax rate increased to 16.7% (from 11.9%), partly due to prior-year tax dispute base effects and Pillar Two taxes.
M&A, divestments and restructuring
2024 acquisitions: Carmot, selected LumiraDx assets and AntlerA; Vacaville manufacturing site divested (cash inflow net CHF ~1.0bn). Global restructuring costs CHF 1.9bn as productivity initiatives continued alongside portfolio prioritisation.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
42002 M
Market cap (USD)
31,649
Daily traded volume (Shares)
268 / 264.4
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
Alexnader Priess
Gabriele Di Benedetto
Karel Bourban
EQUITIES OF THE SAME SECTOR
